ClinicalTrials.gg
RecruitingNCT07304154HERMOSA-2Updated Nov 17, 2026

Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

A Phase 1 interventional study of KITE-363 and Fludarabine in Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis and Multiple Sclerosis, sponsored by Kite, A Gilead Company. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 17, 2026Primary completion movedStudy completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Planned enrollment
26th of 42
57 · median 74
Started
2026
with 3 others
Phase 1
4 of 55
3 open now
Primary completion
2031-12
later than 23 of 24 live
Registered
53rd of 55
by date

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 26th largest by planned enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 23 of the 24 other live ones, and was the 53rd registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.

The primary objectives of this study are:

  • To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases
  • To determine the recommended dose for Phase 1b
  • To evaluate the safety and preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases
03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Myasthenia Gravis
  • Multiple Sclerosis
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age 18 through 65 for relapsing forms of MS, 18 through 75 for progressive forms of MS, above 18 years of age for MG and CIDP.
  • Reproductive status-related eligibility and requirements:

    • Individuals must agree to use protocol-specified method(s) of contraception where applicable

Inclusion Criteria for multiple sclerosis (MS):

MS (Relapsing and progressive forms):

  • Diagnosed with MS according to the 2017 revision of the McDonald diagnostic criteria

Relapsing forms of MS (relapsing-remitting multiple sclerosis (RRMS), active secondary-progressive multiple sclerosis (aSPMS)):

  • Inadequate response to previous therapies is defined as evidence of breakthrough disease activity within 12 months prior to screening while on high efficacy disease-modifying therapy (DMT) OR Inadequate response to previous therapies defined as intolerance to ≥ 2 DMTs due to side effects prohibiting the chronic use of the DMT.
  • Expanded Disability Status Scale (EDSS) 0 to 6.0

Progressive forms of MS (primary-progressive multiple sclerosis (PPMS) and non-active secondary-progressive multiple sclerosis (naSPMS)):

  • Inadequate response to previous therapies is defined as evidence of disease progression within 12 months prior to screening despite standard of care therapy for naSPMS or despite ocrelizumab, where available, for PPMS
  • Absence of clinical relapses for at least 24 months
  • No evidence of Gadolinium enhancing (GadE+) on magnetic resonance imaging (MRI) brain at screening or baseline
  • EDSS of 3 to 6.5 who are ambulatory

Inclusion Criteria for myasthenia gravis (MG):

  • Documentation of autoantibodies against acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or low-density lipoprotein receptor-related protein 4 (LRP4)
  • Diagnosis of MG with generalized weakness meeting criteria as defined by the Myasthenia Gravis Foundation of American (MGFA) classification of II- IV at screening
  • Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 6 (> 50% of the total score due to non-ocular symptoms)
  • Quantitative Myasthenia Gravis (QMG) score ≥ 10
  • Inadequate response to previous therapies while taking at least 2 classes of (ie, , azathioprine (AZA), mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIg), biologics (eg, rituximab, anti-FcRN class, and anti-complement class))
  • Thymectomy allowed if completed ≥ 12 months prior to screening

Inclusion Criteria for chronic inflammatory demyelinating polyneuropathy (CIDP):

  • Probable or definite CIDP as defined by the 2010 European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria, relapsing or progressive forms. Individuals with confirmed IgG4 paranodal antibodies (eg, NF155, CNTN1, Caspr1) are eligible if they meet EFNS/PNS 2010 criteria

    • For the Phase 1b CIDP cohort, diagnosis will be confirmed by independent adjudication once the adjudication committee is established and operational
  • CIDP Disease Activity Status (CDAS) score ≥ 3 at screening and confirmed at the final pre treatment assessment prior to infusion
  • Inflammatory neuropathy cause and treatment (INCAT) score ≥ 3 at screening and confirmed at one of more protocol-defined baseline assessments during the Extended Screening Period with Observational Run-in; individuals must also continue to meet clinical eligibility criteria at the final pre-treatment assessment prior to infusion
  • Inadequate response to previous therapies despite adequate trial of standard of care therapy (≥ 8-12 weeks at standard dosing with stable regimen of either steroids, IVIg, SCIg, plasmapheresis exchange (PLEX), rituximab or anti-FcRN) and either failure, intolerance, or to at least one additional standard therapy (ie, steroids, IVIg, subcutaneous immunoglobulin (SCIg), plasmapheresis exchange (PLEX), rituximab, or anti FcRN), unless medically inappropriate OR Unable to tolerate standard of care resulting in discontinuation due to side effects, with ongoing disease activity
  • Except for nodal/paranodal CIDP, historical documentation of objective improvement in the past 24 months while on IVIg, SCIg, PLEX, or anti-FcRN OR Historical documentation of objective disease worsening in the past 24 months when IVIg, SCIg, PLEX, or anti-FcRN has been reduced or interrupted

Key Exclusion Criteria:

  • History or presence of central nervous system (CNS) or peripheral nervous system disorders before enrollment that may impact cognition, strength, or cause weakness
  • History of or allogeneic stem cell transplant and/or organ transplant
  • History of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)

Exclusion Criteria for MS:

  • Cohort 1 or 2; inability to complete 9-hole Peg Test (9-HPT) in \< 240 seconds and Timed 25 foot Walk (T25FW) \< 150 seconds
  • History of to parenteral administration of gadolinium-based contrast agents
  • Any renal condition that would preclude the administration of gadolinium (for the relapsing forms of MS and progressive forms of MS)
  • Any contraindication to lumbar puncture (LP) (for the relapsing forms of MS and progressive forms of MS)

Exclusion Criteria for MG:

  • Current myasthenic crisis not effectively controlled within 2 weeks before enrollment
  • Thymectomy performed within 12 months of baseline

Exclusion Criteria for CIDP:

  • Pure sensory CIDP and focal CIDP
  • Polyneuropathy of other causes

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
57 participants (estimated)

Study arms

  • Experimental
    Phase 1a: KITE-363 (Dose Escalation) With Lymphodepleting Chemotherapy

    Participants with relapsing forms of multiple sclerosis (RMS), progressive forms of multiple sclerosis (PMS), myasthenia gravis (MG), and/or chronic inflammatory demyelinating polyneuropathy (CIDP) will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by infusion of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose.

    Biological: KITE-363 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Phase 1a: KITE-363 (Dose Escalation) Without Lymphodepleting Chemotherapy

    Participants with RMS, PMS, MG, and/or CIDP will receive infusion of KITE-363 CAR transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose.

    Biological: KITE-363

  • Experimental
    Phase 1b: KITE-363 (Dose Expansion)

    Participants with RMS, PMS, MG, and/or CIDP will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed Phase 1a recommended dose of KITE-363 CAR T cells.

    Biological: KITE-363 · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • BiologicalKITE-363

    A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.

  • Administered intravenously

  • Administered intravenously

06

What researchers measure

Primary outcomes

  1. Phase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)

    Time frame: Up to 3 years

  2. Phase 1a: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363

    Time frame: Up to 28 days

  3. Phase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEs

    Time frame: Up to 3 years

  4. Phase 1b: Relapsing Forms of MS (RRMS) and Active Secondary-progressive Multiple Sclerosis (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12

    This will be reported in participants with relapsing forms of Multiple Sclerosis MS (RRMS) and (aSPMS).

    Time frame: Week 12

  5. Phase 1b: Relapsing Forms of MS (RRMS and aSPMS): Number of New and/or Enlarging T2 Lesions on MRI at Week 12

    Time frame: Week 12

  6. Phase 1b: Progressive Forms of MS (PPMS) and Non-active Secondary-progressive Multiple Sclerosis (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)

    Time frame: Up to 3 years

  7. Phase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) Responders

    The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

    Time frame: Up to 3 years

  8. Phase 1b: CIDP: Proportion of Participants with a ≥ 2 Points Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy

    Clinical improvement will be analyzed using adjusted inflammatory neuropathy cause and treatment (aINCAT) scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with chronic inflammatory demyelinating polyneuropathy (CIDP). The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate clinical improvement.

    Time frame: Up to 3 years

Secondary outcomes

  1. Relapsing forms of MS (RRMS and aSPMS): Annual Relapse Rate

    Proportion of participants with annual relapse.

    Time frame: Up to 3 years

  2. Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-12

    Time frame: Up to 3 years

  3. Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-24

    Time frame: Up to 3 years

  4. Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-12

    Time frame: Up to 3 years

  5. Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-24

    Time frame: Up to 3 years

  6. Progressive forms of MS (PPMS and naSPMS): Proportion of Participants with No Evidence of Disease Activity (NEDA)

    Time frame: Up to 3 years

  7. Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Expanded Disability Status Scale (EDSS) Score Over Time

    EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments.

    Time frame: Up to 3 years

  8. Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Timed 25-foot Walk (T25FW) Score Over Time

    The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment.

    Time frame: Up to 3 years

  9. Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in 9-hole Peg Test Dominant/Non-dominant (9-HPT D/ND) Score Over Time

    The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability.

    Time frame: Up to 3 years

  10. Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Symbol Digit Modalities Test (SDMT) Score Over Time

    SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed.

    Time frame: Up to 3 years

  11. Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-12

    Time frame: Up to 3 years

  12. Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-24

    Time frame: Up to 3 years

  13. Progressive forms of MS (PPMS and naSPMS): Time to Onset of CDP-24

    Time frame: Up to 3 years

  14. Progressive forms of MS (PPMS and naSPMS): Number of new and Enlarging T2 Lesions on MRI

    Time frame: Up to 3 years

  15. Relapsing forms of MS (RRMS and aSPMS): Percentage of Participants With NEDA

    Time frame: Up to 3 years

  16. Progressive forms of MS (PPMS and naSPMS): Change From Baseline in EDSS Over Time

    EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments.

    Time frame: Up to 3 years

  17. Progressive forms of MS (PPMS and naSPMS): Change From Baseline in T25FW Over Time

    The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment.

    Time frame: Up to 3 years

  18. Progressive forms of MS (PPMS and naSPMS): Change From Baseline in 9-HPT D/ND Over Time

    The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability.

    Time frame: Up to 2 years

  19. Progressive forms of MS (PPMS and naSPMS): Change From Baseline in SDMT Over Time

    SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed.

    Time frame: Up to 3 years

  20. MG: Proportion of Participants With at Least a 2-Point or 5 Point Improvement in MG-ADL Score up to Week 24

    The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

    Time frame: Up to 24 weeks

  21. MG: Change From Baseline in MG-ADL Score at Week 24

    The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

    Time frame: Baseline, Week 24

  22. MG: Proportion of Participants With Minimal Symptom Expression (MG-ADL Score of 0 or 1 Point)

    The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

    Time frame: Up to 3 years

  23. MG: Proportion of Participants With at Least a 3-point or 5-point Improvement in Medical Research Council (QMG) Score up to Week 24

    The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment.

    Time frame: Baseline, Week 24

  24. MG: Change From Baseline in QMG Score to Week 24

    The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment.

    Time frame: Baseline, Week 24

  25. MG: Proportion of Participants With at Least a 3-Point Improvement in MG-C Score up to Week 24

    MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment.

    Time frame: Baseline, Up to 24 weeks

  26. Change From Baseline in MG-C Scale Score at Week 24

    MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment.

    Time frame: Baseline, Week 24

  27. MG: Number of Participants With Changes in Myasthenia Gravis Foundation of American Post-Intervention Status (MGFA-PIS), Including Minimal Manifestation, Complete Stable Remission, Pharmacologic Remission

    The MGFA-PIS is a standardized classification system which categorizes outcomes into distinct states such as complete stable remission (CSR), pharmacologic remission (PR), minimal manifestations (MM), improved, unchanged, worse, and exacerbation. CSR indicates no symptoms or signs for at least one year without therapy, while MM reflects minimal weakness without functional limitation.

    Time frame: Up to 3 years

  28. CIDP: Proportion of Participants With a ≥ 1-point Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy

    Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.

    Time frame: Week 24

  29. Proportion of Participants With a ≥ 2-point Improvement from Baseline in aINCAT Score at Week 24

    Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.

    Time frame: Week 24

  30. Proportion of Participants Without aINCAT Deterioration and Without Requirement for CIDP Rescue or Maintenance Therapy Through Week 24

    Time frame: Up to Week 24

  31. Proportion of Participants With ≥ 1-point Improvement in INCAT Lower Limb Score from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy

    Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.

    Time frame: Baseline, up to Week 24

  32. Proportion of Participants Transitioning from INCAT Lower Limb score ≥ 3 (Assistive Device) to ≤ 2 (Independent Ambulation) from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy

    The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.

    Time frame: Baseline, up to Week 24

  33. CIDP: Time to First aINCAT Deterioration

    INCAT is a clinician-administered tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability and lower score would indicate clinical improvement.

    Time frame: Up to 3 years

  34. CIDP: Proportion of Participants With Evidence of Clinical Improvement

    Clinical improvement will be analyzed using inflammatory Rasch-built overall disability scale (I-RODS) scale. I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability.

    Time frame: Up to week 24

  35. CIDP: Change From Baseline Over Time in Adjusted INCAT Score

    INCAT is a tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability.

    Time frame: Up to 3 years

  36. CIDP: Change From Baseline Over Time in 24-Item I-RODS Score

    I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability.

    Time frame: Up to 3 years

  37. CIDP: Change From Baseline Over Time in Medical Research Council (MRC) Sum Score

    MRC Sum Score is a measure to assess muscle strength for people with CIDP. The score ranges from 0 to 60. Higher scores indicate better muscle strength, while lower scores reflect greater weakness.

    Time frame: Up to 3 years

  38. CIDP: Change From Baseline Over Time in Timed Up and Go (TUG) Score

    TUG test is a measure of mobility, balance, and fall risk. The score is recorded in seconds; shorter times indicate better mobility, while longer times suggest impaired balance or gait.

    Time frame: Up to 3 years

  39. CIDP: Change From Baseline Over Time in Mean Grip Strength

    Mean Grip Strength is a quantitative measure of hand and forearm muscle strength. Higher values indicate better muscle strength, while lower values reflect weakness or functional impairment.

    Time frame: Up to 3 years

  40. Proportion of Participants With European Quality of Life 5-Dimension 5-Level Questionnaire (EQ-5D-5L)

    The EQ-5D-5L is a generic measure of health status captured on the day of assessment. Two components comprise the EQ-5D-5L: the EQ-5D descriptive system and the EQ visual analog scale (VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and is divided into 5 levels of severity: "no problems," "slight problems," "moderate problems," "severe problems," and "extreme problems." The EQ-5D-5L VAS is a vertical VAS for recording self-rated current HRQoL, and it ranges from 0, described as "the worst health you can imagine," to 100, described as "the best health you can imagine." EQ-5D-5L will be scored according to the published administration and scoring manual.

    Time frame: Up to 3 years

  41. Proportion of Participants With Chronic Acquired Polyneuropathy Patient-reported Index (CAP-PRI)

    The CAP-PRI is a tool developed to assess the impact of chronic acquired polyneuropathy on participant's quality of life, capturing both physical and psychological symptoms from the participant's perspective. The scoring of the CAP-PRI is typically based on how participants rate their symptoms and overall health across various dimensions, such as sensory symptoms, motor function, pain, emotional well-being, and fatigue. Each dimension of the CAP-PRI is scored separately, and the results are summed up to give an overall score for the participant, with higher scores indicating greater severity or a worse quality of life. Each domain typically uses a Likert scale or similar ordinal scale, where participants rate their experience or symptoms on a scale from 0 to 5.

    Time frame: Up to 3 years

  42. Proportion of Participants With Rasch-Transformed Fatigue Severity Scale (RT-FSS)

    The RT-FSS or FSS-7 is a refined version of the original 9-item Fatigue Severity Scale (FSS-9) designed to improve accuracy in measuring fatigue, particularly in participants with immune-mediated neuropathies. The original 7-point Likert scale was collapsed into a 4-point response category for the remaining items to fulfill strict linearity requirements. It is a linearly weighted scale, meaning its scores provide a more precise, interval-level measurement rather than just an ordinal ranking. It was specifically validated for conditions like Guillain-Barré syndrome and CIDP. This modified scale provides a more stable test-retest reliability. The scale is used to distinguish between different levels of fatigue impact on daily activities, though it may have a ceiling effect for patients with extremely severe symptoms.

    Time frame: Up to 3 years

  43. Levels of T-cells in Blood

    Time frame: Up to 2 years

  44. Pharmacokinetics: Levels of Chimeric Antigen Receptor (CAR) T-cells in Blood

    Time frame: Up to 2 years

  45. Pharmacodynamics Parameters: Levels of B cells in Blood

    Time frame: Up to 2 years

  46. Pharmacodynamics Parameters: Levels of Disease-Specific Biomarkers and Autoantibodies in Blood

    Time frame: Up to 2 years

  47. Pharmacodynamics Parameters: Levels of Cytokines and Chemokines in Blood

    A panel of inflammatory, immuno-modulatory and effector molecules, including cytokines and chemokines, will be measured as units of concentration in serum (e.g. pg/ml) using ligand-based immunoassays such as MSD, Ella and O-link.

    Time frame: Up to 2 years

  48. Proportion of Participants With of Antibodies Against the KITE-363 CAR T cells in Blood

    Time frame: Up to 2 years

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Dec 2031, 68 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jun 2029 → Dec 2031 and completion Jun 2029 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2025
First posted
Dec 26, 2025
StartActual
Apr 10, 2026
Primary completionEst.
Dec 2031was Jun 2029
CompletionEst.
Dec 2031was Jun 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Canada)
  • Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont · Montreal, Canada
  • The Ottawa Hospital - General Campus · Ottawa, Canada
Oct 19, 2026
Primary completion
Jun 2029→Dec 2031
Nov 17, 2026
Study completion
Jun 2029→Dec 2031
Nov 17, 2026
Enrollment
52→57
Oct 19, 2026
Eligibility
7 criteria edited, 3 added
What changed in the criteria
  • AddedAge 18 through 65 for relapsing forms of MS, 18 through 75 for progressive forms of MS, above 18 years of age for MG and CIDP.
  • EditedParticipantsIndividuals must agree to use protocol-specified method(s) of contraception where applicable
  • EditedExpanded Disability Status Scale (EDSS) 0 to 56.50
  • EditedInadequate response to previous therapies while taking at least 2 classes of immunosuppressants (ie, steroids, azathioprine (AZA), mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIg), biologics (eg, rituximab, anti-neonatal fragment crystallizable (Fc) receptor (FcRN) class, and anti-complement class))
  • EditedProbable or definite CIDP as defined by the 2010 European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria, relapsing or progressive forms. Individuals with confirmed IgG4 paranodal antibodies (eg, NF155, CNTN1, Caspr1) are eligible if they meet EFNS/PNS 2010 criteria
  • AddedFor the Phase 1b CIDP cohort, diagnosis will be confirmed by independent adjudication once the adjudication committee is established and operational
  • EditedCIDP Disease Activity Status (CDAS) score ≥ 3 at screening and confirmed at the final pre treatment assessment prior to infusion
  • ChangedBefore Inflammatory neuropathy cause and treatment (INCAT) score ≥ 3Now Inflammatory neuropathy cause and treatment (INCAT) score ≥ 3 at screening and confirmed at one of more protocol-defined baseline assessments during the Extended Screening Period with Observational Run-in; individuals must also continue to meet clinical eligibility criteria at the final pre-treatment assessment prior to infusion
  • EditedInadequate response to previous therapies despite adequate trial of standard of care therapy (≥ 8-12 weeks at standard dosing with stable regimen of either steroids, IVIg, SCIg, plasmapheresis exchange (PLEX), rituximab or anti-FcRN) and either failure, intolerance, or contraindication to at least one additional standard therapy (ie, steroids, IVIg, subcutaneous immunoglobulin (SCIg), plasmapheresis exchange (PLEX), rituximab, or anti FcRN), unless medically inappropriate OR Unable to tolerate standard of care resulting in discontinuation due to side effects, with ongoing disease activity
  • AddedHistory of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
Oct 19, 2026
Interventions
Arm changed Phase 1a: KITE-363 (Dose Escalation)→Phase 1a: KITE-363 (Dose Escalation) With Lymphodepleting Chemotherapy. Arms added: Phase 1a: KITE-363 (Dose Escalation) Without Lymphodepleting Chemotherapy
Oct 19, 2026
Primary outcomes
3 edited, 3 time frame changed
What changed in the outcomes
  • EditedPhase 1b: Relapsing Forms of MS (RRMS) and Active Secondary-progressive Multiple Sclerosis (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12Time frame: Week 12
  • EditedPhase 1b: Progressive Forms of MS (PPMS) and Non-active Secondary-progressive Multiple Sclerosis (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)Time frame: Up to 2 years → Up to 3 years
  • ChangedBefore Phase 1b: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Proportion of Participants with Confirmed Evidence of Clinical Improvement at Week 24Now Phase 1b: CIDP: Proportion of Participants with a ≥ 2 Points Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory TherapyTime frame: Week 24 → Up to 3 years
  • Time framePhase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)Up to 2 years → Up to 3 years
  • Time framePhase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEsUp to 2 years → Up to 3 years
  • Time framePhase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) RespondersUp to Week 24 → Up to 3 years
Oct 19, 2026
Secondary outcomes
3 edited, 19 time frame changed, 7 added, 1 removed, 6 more
What changed in the outcomes
  • EditedCIDP: Time to First Adjusted INCATaINCAT DeteriorationTime frame: Up to 2 years → Up to 3 years
  • EditedCIDP: Change From Baseline Over Time in Mean grip strength assessed by Martin VigorimeterGrip StrengthTime frame: Up to 2 years → Up to 3 years
  • ChangedBefore CIDP: Proportion of Participants With Confirmed Evidence of Clinical ImprovementNow CIDP: Proportion of Participants With a ≥ 1-point Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory TherapyTime frame: Week 48 → Week 24
  • AddedProportion of Participants With a ≥ 2-point Improvement from Baseline in aINCAT Score at Week 24Time frame: Week 24
  • AddedProportion of Participants Without aINCAT Deterioration and Without Requirement for CIDP Rescue or Maintenance Therapy Through Week 24Time frame: Up to Week 24
  • AddedProportion of Participants With ≥ 1-point Improvement in INCAT Lower Limb Score from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory TherapyTime frame: Baseline, up to Week 24
  • AddedProportion of Participants Transitioning from INCAT Lower Limb score ≥ 3 (Assistive Device) to ≤ 2 (Independent Ambulation) from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory TherapyTime frame: Baseline, up to Week 24
  • AddedProportion of Participants With European Quality of Life 5-Dimension 5-Level Questionnaire (EQ-5D-5L)Time frame: Up to 3 years
  • AddedProportion of Participants With Chronic Acquired Polyneuropathy Patient-reported Index (CAP-PRI)Time frame: Up to 3 years
  • AddedProportion of Participants With Rasch-Transformed Fatigue Severity Scale (RT-FSS)Time frame: Up to 3 years
  • RemovedCIDP: Time to Disease Progression by I-RODSTime frame: Baseline, Up to 48 Weeks
  • Time frameRelapsing forms of MS (RRMS and aSPMS): Annual Relapse RateUp to 2 years → Up to 3 years
  • Time frameRelapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-12Up to 2 years → Up to 3 years
  • Time frameRelapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-24Up to 2 years → Up to 3 years
  • Time frameRelapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-12Up to 2 years → Up to 3 years
  • Time frameRelapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-24Up to 2 years → Up to 3 years
  • Time frameProgressive forms of MS (PPMS and naSPMS): Proportion of Participants with No Evidence of Disease Activity (NEDA)Up to 2 years → Up to 3 years
  • Time frameRelapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Expanded Disability Status Scale (EDSS) Score Over TimeUp to 2 years → Up to 3 years
  • Time frameRelapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Timed 25-foot Walk (T25FW) Score Over TimeUp to 2 years → Up to 3 years
  • Time frameRelapsing Forms of MS (RRMS and aSPMS): Change From Baseline in 9-hole Peg Test Dominant/Non-dominant (9-HPT D/ND) Score Over TimeUp to 2 years → Up to 3 years
  • Time frameRelapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Symbol Digit Modalities Test (SDMT) Score Over TimeUp to 2 years → Up to 3 years
  • Time frameProgressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-12Up to 2 years → Up to 3 years
  • Time frameProgressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-24Up to 2 years → Up to 3 years
  • Time frameProgressive forms of MS (PPMS and naSPMS): Time to Onset of CDP-24Up to 2 years → Up to 3 years
  • Time frameProgressive forms of MS (PPMS and naSPMS): Number of new and Enlarging T2 Lesions on MRIUp to 2 years → Up to 3 years
  • Time frameRelapsing forms of MS (RRMS and aSPMS): Percentage of Participants With NEDAUp to 2 years → Up to 3 years
  • Time frameProgressive forms of MS (PPMS and naSPMS): Change From Baseline in EDSS Over TimeUp to 2 years → Up to 3 years
  • Time frameProgressive forms of MS (PPMS and naSPMS): Change From Baseline in T25FW Over TimeUp to 2 years → Up to 3 years
  • Time frameProgressive forms of MS (PPMS and naSPMS): Change From Baseline in SDMT Over TimeUp to 2 years → Up to 3 years
  • Time frameMG: Proportion of Participants With Minimal Symptom Expression (MG-ADL Score of 0 or 1 Point)Up to 2 years → Up to 3 years
  • …and 6 more, on the record history on ClinicalTrials.gov ↗
Oct 19, 2026
Title
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/RefractoryParticipants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Oct 19, 2026
Show all 2 updates
  1. Nov 17, 2026
    Primary completion Jun 2029→Dec 2031
    Study completion Jun 2029→Dec 2031
    + 1 other change: verification date
  2. Oct 19, 2026
    2 sites added
    Show 2 added (2 Canada)
    • Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont · Montreal, Canada
    • The Ottawa Hospital - General Campus · Ottawa, Canada
    Enrollment 52→57
    Eligibility 7 criteria edited, 3 added
    What changed in the criteria
    • AddedAge 18 through 65 for relapsing forms of MS, 18 through 75 for progressive forms of MS, above 18 years of age for MG and CIDP.
    • EditedParticipantsIndividuals must agree to use protocol-specified method(s) of contraception where applicable
    • EditedExpanded Disability Status Scale (EDSS) 0 to 56.50
    • EditedInadequate response to previous therapies while taking at least 2 classes of immunosuppressants (ie, steroids, azathioprine (AZA), mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIg), biologics (eg, rituximab, anti-neonatal fragment crystallizable (Fc) receptor (FcRN) class, and anti-complement class))
    • EditedProbable or definite CIDP as defined by the 2010 European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria, relapsing or progressive forms. Individuals with confirmed IgG4 paranodal antibodies (eg, NF155, CNTN1, Caspr1) are eligible if they meet EFNS/PNS 2010 criteria
    • AddedFor the Phase 1b CIDP cohort, diagnosis will be confirmed by independent adjudication once the adjudication committee is established and operational
    • EditedCIDP Disease Activity Status (CDAS) score ≥ 3 at screening and confirmed at the final pre treatment assessment prior to infusion
    • ChangedBefore Inflammatory neuropathy cause and treatment (INCAT) score ≥ 3Now Inflammatory neuropathy cause and treatment (INCAT) score ≥ 3 at screening and confirmed at one of more protocol-defined baseline assessments during the Extended Screening Period with Observational Run-in; individuals must also continue to meet clinical eligibility criteria at the final pre-treatment assessment prior to infusion
    • EditedInadequate response to previous therapies despite adequate trial of standard of care therapy (≥ 8-12 weeks at standard dosing with stable regimen of either steroids, IVIg, SCIg, plasmapheresis exchange (PLEX), rituximab or anti-FcRN) and either failure, intolerance, or contraindication to at least one additional standard therapy (ie, steroids, IVIg, subcutaneous immunoglobulin (SCIg), plasmapheresis exchange (PLEX), rituximab, or anti FcRN), unless medically inappropriate OR Unable to tolerate standard of care resulting in discontinuation due to side effects, with ongoing disease activity
    • AddedHistory of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
    Primary outcomes 3 edited, 3 time frame changed
    What changed in the outcomes
    • EditedPhase 1b: Relapsing Forms of MS (RRMS) and Active Secondary-progressive Multiple Sclerosis (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12Time frame: Week 12
    • EditedPhase 1b: Progressive Forms of MS (PPMS) and Non-active Secondary-progressive Multiple Sclerosis (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)Time frame: Up to 2 years → Up to 3 years
    • ChangedBefore Phase 1b: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Proportion of Participants with Confirmed Evidence of Clinical Improvement at Week 24Now Phase 1b: CIDP: Proportion of Participants with a ≥ 2 Points Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory TherapyTime frame: Week 24 → Up to 3 years
    • Time framePhase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)Up to 2 years → Up to 3 years
    • Time framePhase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEsUp to 2 years → Up to 3 years
    • Time framePhase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) RespondersUp to Week 24 → Up to 3 years
    Secondary outcomes 3 edited, 19 time frame changed, 7 added, 1 removed, 6 more
    What changed in the outcomes
    • EditedCIDP: Time to First Adjusted INCATaINCAT DeteriorationTime frame: Up to 2 years → Up to 3 years
    • EditedCIDP: Change From Baseline Over Time in Mean grip strength assessed by Martin VigorimeterGrip StrengthTime frame: Up to 2 years → Up to 3 years
    • ChangedBefore CIDP: Proportion of Participants With Confirmed Evidence of Clinical ImprovementNow CIDP: Proportion of Participants With a ≥ 1-point Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory TherapyTime frame: Week 48 → Week 24
    • AddedProportion of Participants With a ≥ 2-point Improvement from Baseline in aINCAT Score at Week 24Time frame: Week 24
    • AddedProportion of Participants Without aINCAT Deterioration and Without Requirement for CIDP Rescue or Maintenance Therapy Through Week 24Time frame: Up to Week 24
    • AddedProportion of Participants With ≥ 1-point Improvement in INCAT Lower Limb Score from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory TherapyTime frame: Baseline, up to Week 24
    • AddedProportion of Participants Transitioning from INCAT Lower Limb score ≥ 3 (Assistive Device) to ≤ 2 (Independent Ambulation) from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory TherapyTime frame: Baseline, up to Week 24
    • AddedProportion of Participants With European Quality of Life 5-Dimension 5-Level Questionnaire (EQ-5D-5L)Time frame: Up to 3 years
    • AddedProportion of Participants With Chronic Acquired Polyneuropathy Patient-reported Index (CAP-PRI)Time frame: Up to 3 years
    • AddedProportion of Participants With Rasch-Transformed Fatigue Severity Scale (RT-FSS)Time frame: Up to 3 years
    • RemovedCIDP: Time to Disease Progression by I-RODSTime frame: Baseline, Up to 48 Weeks
    • Time frameRelapsing forms of MS (RRMS and aSPMS): Annual Relapse RateUp to 2 years → Up to 3 years
    • Time frameRelapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-12Up to 2 years → Up to 3 years
    • Time frameRelapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-24Up to 2 years → Up to 3 years
    • Time frameRelapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-12Up to 2 years → Up to 3 years
    • Time frameRelapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-24Up to 2 years → Up to 3 years
    • Time frameProgressive forms of MS (PPMS and naSPMS): Proportion of Participants with No Evidence of Disease Activity (NEDA)Up to 2 years → Up to 3 years
    • Time frameRelapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Expanded Disability Status Scale (EDSS) Score Over TimeUp to 2 years → Up to 3 years
    • Time frameRelapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Timed 25-foot Walk (T25FW) Score Over TimeUp to 2 years → Up to 3 years
    • Time frameRelapsing Forms of MS (RRMS and aSPMS): Change From Baseline in 9-hole Peg Test Dominant/Non-dominant (9-HPT D/ND) Score Over TimeUp to 2 years → Up to 3 years
    • Time frameRelapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Symbol Digit Modalities Test (SDMT) Score Over TimeUp to 2 years → Up to 3 years
    • Time frameProgressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-12Up to 2 years → Up to 3 years
    • Time frameProgressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-24Up to 2 years → Up to 3 years
    • Time frameProgressive forms of MS (PPMS and naSPMS): Time to Onset of CDP-24Up to 2 years → Up to 3 years
    • Time frameProgressive forms of MS (PPMS and naSPMS): Number of new and Enlarging T2 Lesions on MRIUp to 2 years → Up to 3 years
    • Time frameRelapsing forms of MS (RRMS and aSPMS): Percentage of Participants With NEDAUp to 2 years → Up to 3 years
    • Time frameProgressive forms of MS (PPMS and naSPMS): Change From Baseline in EDSS Over TimeUp to 2 years → Up to 3 years
    • Time frameProgressive forms of MS (PPMS and naSPMS): Change From Baseline in T25FW Over TimeUp to 2 years → Up to 3 years
    • Time frameProgressive forms of MS (PPMS and naSPMS): Change From Baseline in SDMT Over TimeUp to 2 years → Up to 3 years
    • Time frameMG: Proportion of Participants With Minimal Symptom Expression (MG-ADL Score of 0 or 1 Point)Up to 2 years → Up to 3 years
    • …and 6 more, on the record history on ClinicalTrials.gov ↗
    Interventions Arm changed Phase 1a: KITE-363 (Dose Escalation)→Phase 1a: KITE-363 (Dose Escalation) With Lymphodepleting Chemotherapy. Arms added: Phase 1a: KITE-363 (Dose Escalation) Without Lymphodepleting Chemotherapy
    Title A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/RefractoryParticipants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07304154
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Apr 10, 2026
Primary completion
Dec 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Medical Information
Contact
medinfo@kitepharma.com
844-454-5483(1-844-454-KITE)
Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-CD19/CD20 CAR-T Cells KITE-363

Start the discussion